A method to label monoclonal antibodies (MAbs) with Zr-88 and Zr-89 has been developed and tested on the MAbs 323/A3 and E48. Methods: The bifunctional chelating agent desferal (Df) was linked through a thioether bond to the Mabs. Labeling was accomplished by addition of the premodified antibodies to isolated Zr. The retention of the in vivo behavior of the MAbs was determined by comparing the biodistribution of Zr-88-labeled MAbs with those of I-123 and Tc-99m in mice bearing tumor xenografts. Results: The labeling was simple and the yields were high (above 90%). The obtained conjugates retained their immunoreactivity (>80). The blood clearance and biodistribution of Zr-labeled MAbs resembled those of the reference conjugates. The Zr-Df...
Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to c...
Monoclonal antibodies (MAbs) labeled with radiometallonuclides via metal chelators are being investi...
Our previous studies on the preparation of 186Re-MAb conjugates for clinical radioimmunotherapy (RIT...
A method to label monoclonal antibodies (MAbs) with Zr-88 and Zr-89 has been developed and tested on...
Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor...
89Zr-immuno-PET is an attractive option for the in vivo evaluation of monoclonal antibodies (mAbs). ...
Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visu...
Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor...
To label proteins with positron emitters with a half life in the order of days, a method has been de...
Immuno-PET as a scouting procedure before radioimmuno-therapy (RIT) aims at confirming tumor targeti...
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under clinical development...
A detailed technical protocol is provided for reproducible and aseptical production of stable 186Re-...
Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from 111In imaging d...
Contains fulltext : 181624.pdf (Publisher’s version ) (Open Access)Immuno-positron...
The humanized monoclonal antibody with high affinity for the human epidermal growth factor receptor ...
Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to c...
Monoclonal antibodies (MAbs) labeled with radiometallonuclides via metal chelators are being investi...
Our previous studies on the preparation of 186Re-MAb conjugates for clinical radioimmunotherapy (RIT...
A method to label monoclonal antibodies (MAbs) with Zr-88 and Zr-89 has been developed and tested on...
Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor...
89Zr-immuno-PET is an attractive option for the in vivo evaluation of monoclonal antibodies (mAbs). ...
Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visu...
Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor...
To label proteins with positron emitters with a half life in the order of days, a method has been de...
Immuno-PET as a scouting procedure before radioimmuno-therapy (RIT) aims at confirming tumor targeti...
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under clinical development...
A detailed technical protocol is provided for reproducible and aseptical production of stable 186Re-...
Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from 111In imaging d...
Contains fulltext : 181624.pdf (Publisher’s version ) (Open Access)Immuno-positron...
The humanized monoclonal antibody with high affinity for the human epidermal growth factor receptor ...
Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to c...
Monoclonal antibodies (MAbs) labeled with radiometallonuclides via metal chelators are being investi...
Our previous studies on the preparation of 186Re-MAb conjugates for clinical radioimmunotherapy (RIT...